Journal of Clinical Oncology· 2012Q1

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

Gregory Cairncross, Meihua Wang, Edward Shaw, Robert B. Jenkins et al.

1,165citations
Q1SCImago
2012year

Short summary

Chemoradiotherapy (PCV plus RT) significantly improved overall survival for anaplastic oligodendroglioma patients with 1p/19q codeleted tumors, doubling median survival to 14.7 years compared to radiotherapy alone (7.3 years).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine